Mayo Test Catalog, (Sorted By Test Name) - Mayo Medical ...

FBOMB
90174
BAP
82985
3 3.50-17.4 Positive
4 17.5-49.9 Strongly positive
5 50.0-99.9 Strongly positive
6 > or =100 Strongly positive Reference values
apply to all ages.
Clinical References: Homburger HA: Allergic diseases. In Clinical Diagnosis and Management by
Laboratory Methods. 21st edition. Edited by RA McPherson, MR Pincus. New York, WB Saunders
Company, 2007, Chapter 53, Part VI, pp 961-971
Bombesin
Clinical Information: Bombesin is a 14 amino acid peptide with strong Gastrin and gastric acid
releasing properties. Bombesin also increases pancreatic enzyme output. Bombesin is found in high
concentrations in the lung and has been proposed as a marker for oat-cell carcinoma. Bombesin
hypersecretion has been associated with several physiological effects including anorexia, hypothermia,
and hyperglycemia. It is also increased in small lung cell carcinoma and tumors of the APUD series.
Bombesin infusion increases Neurotensin, Gastric Inhibitory Polypeptide and Enteroglucagon levels,
but has no effect on pancreatic Glucagon.
Reference Values:
50-250 pg/mL
This test was developed and its performance characteristics determined by Inter Science Institute. It
has not been cleared or approved by the US Food and Drug Administration. The FDA has determined
that such clearance or approval is not necessary.
Test Performed by: Inter Science Inst
944 West Hyde Park
Inglewood, CA 90302
Bone Alkaline Phosphatase, Serum
Clinical Information: Bone alkaline phosphatase (BAP) is the bone-specific isoform of alkaline
phosphatase. A glycoprotein that is found on the surface of osteoblasts, BAP reflects the biosynthetic
activity of these bone-forming cells. BAP has been shown to be a sensitive and reliable indicator of
bone metabolism.(1) Normal bone is constantly undergoing remodeling in which bone degradation or
resorption is balanced by bone formation. This process is necessary for maintaining bone health. If the
process becomes uncoupled and the rate of resorption exceeds the rate of formation, the resulting bone
loss can lead to osteoporosis and, consequently, a higher susceptibility to fractures. Osteoporosis is a
metabolic bone disease characterized by low bone mass and abnormal bone microarchitecture. It can
result from a number of clinical conditions including states of high bone turnover, endocrine disorders
(primary and secondary hyperparathyroidism and thyrotoxicosis), osteomalacia, renal failure,
gastrointestinal diseases, long-term corticosteroid therapy, multiple myeloma, and cancer metastatic to
the bones. Paget disease is another common metabolic bone disease caused by excessive rates of bone
remodeling resulting in local lesions of abnormal bone matrix. These lesions can result in fractures or
neurological involvement. Antiresorptive therapies are used to restore the normal bone structure.
Useful For: Diagnosis and assessment of severity of metabolic bone disease including Paget disease,
osteomalacia, and other states of high bone turnover Monitoring efficacy of antiresorptive therapies
including postmenopausal osteoporosis treatment
Interpretation: Bone alkaline phosphatase (BAP) concentration is high in Paget disease and
osteomalacia. Antiresorptive therapies lower BAP from baseline measurements in Paget disease,
Current as of January 3, 2013 2:22 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 285